A randomised controlled trial of fixed-dose combination medication and usual care in those at high risk of cardiovascular disease.Acronym: UMPIRE - Use of a Multidrug Pill In Reducing cardiovascular Events

Imperial College London0 个研究点目标入组 2,000 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•* Adults (≥ 18 years)
•* The participant is able to give informed consent.
•* Established atherothrombotic cardiovascular disease (CVD) or high cardiovascular risk, of for individuals without established cardiovascular disease, a calculated 5 year CVD risk of 15% or greater (calculated using the 1991 Anderson Framingham risk equation with adjustments as defined by the New Zealand Guidelines Group recommendations)
•* The trial Investigator considers that each of the polypill components are indicated
•* The trial Investigator is unsure as to whether a polypill-based strategy or usual care is better.

•* Contraindication to any of the components of the polypill (e.g. known intolerance to aspirin, statins, or ACE inhibitors,pregnancy or likely to become pregnant during the treatment period).
•* The treating doctor considers that changing a participant's cardiovascular medications would put the participant at risk (e.g. symptomatic heart failure, high dose βblocker required to manage angina or for rate control in atrial fibrillation,accelerated hypertension, severe renal insufficiency, a history of severe resistant hypertension)
•* Known situation where medication regimen might be altered for a significant length of time, e.g. current acute cardiovascular event, planned coronary bypass graft operation.
•* Unlikely to complete the trial (e.g. lifethreatening condition other than cardiovascular disease) or adhere to the trial procedures or attend study visits (e.g. major psychiatric condition, dementia).

发起方